About: NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Sector: Healthcare
Industry: Biotechnology
Latest price: $21.26 (-3.93%)
NAMS NASDAQ NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V. Ordinary Shares share price
NAMS price activity
Último preço
$ 21,260
Variação (24h)
-0,87 USD (-3,93%)
Volume
1.61M
Volume (média 4 sem.)
-
Abertura
$ 22,00
Variação do dia
$ 20,94 - $ 22,00
Fechamento anterior
$ 22,13
Último negócio
08 Oct, 8:00 pm GMT+0
Atrasado
08 Oct, 8:00 pm GMT+0
NAMS price performance
Atrasado
08 Oct, 8:00 pm GMT+0
quote.marketSignals